CBER Director Zoon To Leave FDA In Mid-January To Return To NIH
Executive Summary
FDA will be initiating a search for a new head of the reorganized Center for Biologics Evaluation & Research following the departure of Director Kathryn Zoon, PhD, in mid-January
You may also be interested in...
CDER May Form New Office Of Drug Evaluation For CBER Reviewers
The Center for Drug Evaluation & Research is considering creating a sixth Office of Drug Evaluation to incorporate the CBER review divisions that are transferring to the drug center
CDER May Form New Office Of Drug Evaluation For CBER Reviewers
The Center for Drug Evaluation & Research is considering creating a sixth Office of Drug Evaluation to incorporate the CBER review divisions that are transferring to the drug center
CBER Director Goodman Fits New Center Mission, Offers Continuity For Staff
The elevation of Center for Biologics Evaluation & Research Deputy Director Jesse Goodman, MD, to the top position in the center emphasizes continuity during a time of change for FDA's biologics staff